Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.

Source:http://linkedlifedata.com/resource/pubmed/id/3895098

Download in:

View as

General Info

PMID
3895098